PriceTargets.com logo

Sino Biopharmaceutical - SBMFF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.37 As of 09/20/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SBMFF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sino Biopharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBMFF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBMFF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.37.

This chart shows the closing price for SBMFF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sino Biopharmaceutical. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/2/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy
11/3/2020Daiwa Capital MarketsInitiated CoverageBuy
8/20/2020MacquarieDowngradeOutperform ➝ Neutral
5/12/2020Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
3/19/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
(Data available from 9/22/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sino Biopharmaceutical logo
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Read More

Today's Range

Now: $0.37
Low: $0.37
High: $0.37

50 Day Range

MA: $0.40
Low: $0.37
High: $0.45

52 Week Range

Now: $0.37
Low: $0.37
High: $0.63

Volume

N/A

Average Volume

114 shs

Market Capitalization

$6.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Sino Biopharmaceutical?

The following Wall Street analysts have issued research reports on Sino Biopharmaceutical in the last twelve months:
View the latest analyst ratings for SBMFF.

What is the current price target for Sino Biopharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Sino Biopharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sino Biopharmaceutical in the next year.
View the latest price targets for SBMFF.

What is the current consensus analyst rating for Sino Biopharmaceutical?

Sino Biopharmaceutical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBMFF.

What other companies compete with Sino Biopharmaceutical?

Other companies that are similar to Sino Biopharmaceutical include Amplifon, SWEDISH ORPHAN/S, Hikma Pharmaceuticals, Orion Oyj and Aspen Pharmacare. Learn More about companies similar to Sino Biopharmaceutical.

How do I contact Sino Biopharmaceutical's investor relations team?

Sino Biopharmaceutical's physical mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company's listed phone number is 852-2802-9886 and its investor relations email address is [email protected]. The official website for Sino Biopharmaceutical is www.sinobiopharm.com. Learn More about contacing Sino Biopharmaceutical investor relations.